Rates of cervical precancer dropped nearly 80% between 2008 and 2022 among screened women aged 20 to 24, according to the latest Morbidity and Mortality Weekly Report from Centers for Disease Control and Prevention (CDC). The report notes that women in this age group are those most likely to have received the HPV vaccine.
Related Topics
The Overview: June 2026
Nearly 500 people have already registered for OCRA’s International Gynecologic Cancer Conference®—the largest conference dedicated to the gynecologic cancer community—taking place on September 16–17. The conference is free, online, and open to all, and will include programming for ovarian, endometrial, cervical, and rare gynecologic cancers. For the first time, each of these diseases will have a dedicated Ask the Experts session. Learn … Continued
Inside the Think Tank: Stopping Ovarian Cancer Before it Starts
On June 1–2, the Ovarian Cancer Observatory—part of OCRA’s broader investment in research initiatives—convened its first in-person Forum in Vancouver. Roughly 50 of the field’s brightest clinicians, pathologists, and epidemiologists gathered for what became, in essence, a two-day think tank on preventing ovarian cancer. The Observatory is funded through a grant from OCRA and was … Continued
OCRA-Funded ROCCA Platform Launches to Accelerate Rare Ovarian Cancer Research
OCRA is proud to announce the launch of the Rare Ovarian Cancer Collaborative Analytics (ROCCA) Platform, an international federated data network funded by OCRA to connect researchers globally and accelerate breakthroughs in rare ovarian cancer research. A collaborative approach to research for rare ovarian cancer ROCCA is launching with two foundational projects: one in mucinous … Continued
